<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060176</url>
  </required_header>
  <id_info>
    <org_study_id>TA Trial China</org_study_id>
    <nct_id>NCT01060176</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid on Blood Loss and Transfusion in Cardiac Surgery</brief_title>
  <official_title>A Multicenter Clinical Trial of Tranexamic Acid on Blood Loss and Allogeneic Transfusions in Cardiopulmonary Bypass Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid is thought to be a promising substitute for aprotinin when the latter has
      seceded in 2007. Yet the ideal dosage and dosing regimen of tranexamic acid in
      cardiopulmonary bypass cardiac surgery in Chinese population remains controversial. The
      current study includes patients receiving valvular replacement and coronary artery bypass
      surgery. Different dosage of tranexamic acid is delivered and blood loss, transfusions and
      clinical outcomes are recorded. The study hypothesis is that tranexamic acid could reduce
      blood loss and allogeneic transfusion in cardiopulmonary bypass cardiac surgery. Furthermore,
      tranexamic acid could decrease inflammatory reaction in cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss (chest drainage) postoperatively</measure>
    <time_frame>on the 30th day postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Allogeneic transfusions</measure>
    <time_frame>on the 30th day postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU and hospital postoperatively</measure>
    <time_frame>on the 30th day postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of reexploration for hemostasis</measure>
    <time_frame>on the 30th day postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulatory and fibrinolytic status</measure>
    <time_frame>12hrs and 24hrs postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokines</measure>
    <time_frame>12hrs and 24hrs postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastography</measure>
    <time_frame>12hrs and 24hrs postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>High dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Routine therapy without tranexamic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>High, medium and low dosage, loading dose followed by continuous infusion in operation</description>
    <arm_group_label>High dosage</arm_group_label>
    <arm_group_label>Medium dosage</arm_group_label>
    <arm_group_label>Low dosage</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatic or recessive valvular disease patients requiring valvular replacement
             surgery with cardiopulmonary bypass

          -  Coronary artery disease patients requiring coronary artery bypass surgery with
             cardiopulmonary bypass

        Exclusion Criteria:

          -  Non-primary cardiac surgery

          -  Definite liver and renal dysfunction

          -  Disorder in coagulation function

          -  Drugs or interventions influencing inflammatory status such as ulinastatin

          -  Allergy

          -  Pregnancy and lactation

          -  Disabled in spirit or law

          -  Fatal conditions such as tumour
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihuan Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lihuan Li, MD</last_name>
    <phone>86-10-88398184</phone>
    <email>llhfw@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Shi, MD</last_name>
    <phone>86-10-88398082</phone>
    <email>shiandypumc@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihuan Li, MD</last_name>
      <phone>86-10-88398184</phone>
      <email>llhfw@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Jia Shi, MD</last_name>
      <phone>86-10-88398082</phone>
      <email>shiandypumc@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lihuan Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia Shi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Attending doctor of the department of anesthesiology and critical care, Fuwai hospital, NCCD, PUMC &amp; CAMS</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>cardiac surgery procedures</keyword>
  <keyword>hemostasis</keyword>
  <keyword>anti-inflammation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

